Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 140 articles: HTML format

Single Articles

April 2024
1. ZHENG SM, Feng YC, Zhu Q, Li RQ, et al
   MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer.
   Cancer Res. 2024 Apr 9:OF1-OF15. doi: 10.1158/0008-5472.CAN-23-3046.
   PubMed     Abstract available
   
   
   March 2024
2. ZHANG M, Zhou K, Wang Z, Liu T, et al
   A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer.
   Cancer Res. 2024 Mar 20. doi: 10.1158/0008-5472.CAN-23-2640.
   PubMed     Abstract available
   
   
   
3. QIU Y, Wang X, Sun Y, Jin T, et al
   ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
   Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
   PubMed     Abstract available
   
   
   February 2024
4. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
   PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
   Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
   PubMed     Abstract available
   
   
   
5. YAN L, Wu M, Wang T, Yuan H, et al
   Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion.
   Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2390.
   PubMed     Abstract available
   
   
   
6. BERNARD MJ, Goldstein AS
   A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer.
   Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0460.
   PubMed     Abstract available
   
   
   
7. GEDIK ME, Saatci O, Oberholtzer N, Uner M, et al
   Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer.
   Cancer Res. 2024 Feb 6. doi: 10.1158/0008-5472.CAN-23-2812.
   PubMed     Abstract available
   
   
   January 2024
8. MARQUEZ-PALENCIA M, Reza Herrera L, Parida PK, Ghosh S, et al
   AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.
   Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-23-1459.
   PubMed     Abstract available
   
   
   
9. SOOSAINATHAN A, Iravani M, El-Botty R, Alexander J, et al
   Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
   Cancer Res. 2024;84:17-25.
   PubMed     Abstract available
   
   
   December 2023
10. KIM S, Oh J, Park C, Kim M, et al
    FAM3C in cancer-associated adipocytes promotes breast cancer cell survival and metastasis.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-1641.
    PubMed     Abstract available
    
    
    
11. LIN P, Lourenco C, Cruickshank J, Palomero L, et al
    Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.
    Cancer Res. 2023;83:4015-4029.
    PubMed     Abstract available
    
    
    
12. COMPTON ZT, Mallo D, Maley CC
    Stronger Together: Cancer Clones Cooperate to Alleviate Growth Barriers in Critical Cancer Progression Transitions.
    Cancer Res. 2023;83:4013-4014.
    PubMed     Abstract available
    
    
    
13. MICHAUD DE, Guerriero JL
    Myeloid cells pave the metastatic road in breast cancer.
    Cancer Res. 2023 Dec 6. doi: 10.1158/0008-5472.CAN-23-3803.
    PubMed     Abstract available
    
    
    
14. FAN H, Xu Z, Yao K, Zheng B, et al
    Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1443.
    PubMed     Abstract available
    
    
    November 2023
15. WALL SW, Echeverria GV
    Avoiding Extinction: Cancer-Associated Fibroblasts Help Triple-Negative Breast Cancer Outrun Chemotherapy.
    Cancer Res. 2023;83:3667-3669.
    PubMed     Abstract available
    
    
    
16. XU Y, Li X, Zhang S, Tang M, et al
    CircMMP2(6,7) cooperates with beta-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-1899.
    PubMed     Abstract available
    
    
    October 2023
17. AHN S, Park JH, Grimm SL, Piyarathna DWB, et al
    Metabolomic rewiring promotes endocrine therapy resistance in breast cancer.
    Cancer Res. 2023 Oct 31. doi: 10.1158/0008-5472.CAN-23-0184.
    PubMed     Abstract available
    
    
    
18. JACOBS C, Shah S, Lu WC, Ray H, et al
    HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T cell recruitment.
    Cancer Res. 2023 Oct 27. doi: 10.1158/0008-5472.CAN-23-0902.
    PubMed     Abstract available
    
    
    
19. MIROSHNYCHENKO D, Miti T, Kumar P, Miller A, et al
    Stroma-mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles.
    Cancer Res. 2023 Oct 4. doi: 10.1158/0008-5472.CAN-23-0398.
    PubMed     Abstract available
    
    
    
20. WU J, Subbiah V
    RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
    Cancer Res. 2023;83:3159-3161.
    PubMed     Abstract available
    
    
    
21. WINGATE HF, Keyomarsi K
    Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All.
    Cancer Res. 2023;83:3165-3167.
    PubMed     Abstract available
    
    
    
22. NAVARRO-YEPES J, Kettner NM, Rao X, Bishop CS, et al
    Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
    Cancer Res. 2023;83:3264-3283.
    PubMed     Abstract available
    
    
    September 2023
23. LAWSON M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, et al
    The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance.
    Cancer Res. 2023 Sep 19. doi: 10.1158/0008-5472.CAN-23-0694.
    PubMed     Abstract available
    
    
    
24. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    PubMed     Abstract available
    
    
    August 2023
25. COHEN N, Mundhe D, Deasy SK, Adler O, et al
    Breast cancer-secreted factors promote lung metastasis by signaling systemically to induce a fibrotic pre-metastatic niche.
    Cancer Res. 2023 Aug 7:CAN-22-3707. doi: 10.1158/0008-5472.CAN-22-3707.
    PubMed     Abstract available
    
    
    
26. ZHU YY, Song L, Zhang YQ, Liu WL, et al
    Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging.
    Cancer Res. 2023 Aug 4:CAN-22-3432. doi: 10.1158/0008-5472.CAN-22-3432.
    PubMed     Abstract available
    
    
    
27. MATHUR D, Liao C, Lin W, La Ferlita A, et al
    The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.
    Cancer Res. 2023 Aug 1:CAN-23-0153. doi: 10.1158/0008-5472.CAN-23-0153.
    PubMed     Abstract available
    
    
    
28. SCHMIT SL, Purrington K, Figueiredo JC
    Efforts to Grow Genomic Research in Ancestrally Diverse and Admixed Populations.
    Cancer Res. 2023;83:2443-2444.
    PubMed     Abstract available
    
    
    
29. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    PubMed     Abstract available
    
    
    
30. SHU X, Li J, Chan UI, Su SM, et al
    BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
    Cancer Res. 2023;83:2614-2633.
    PubMed     Abstract available
    
    
    
31. DING YC, Song H, Adamson AW, Schmolze D, et al
    Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Cancer Res. 2023;83:2600-2613.
    PubMed     Abstract available
    
    
    July 2023
32. AMAYA RAMIREZ CC, Loayza-Puch F
    Breast Cancer Metastatic Progression Requires mRNA Posttranscriptional Suppression.
    Cancer Res. 2023 Jul 19:OF1-OF2. doi: 10.1158/0008-5472.CAN-23-1729.
    PubMed     Abstract available
    
    
    
33. WANG Z, Zhang N, Zhang M, Jiang Y, et al
    GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner.
    Cancer Res. 2023 Jul 18:CAN-22-3471. doi: 10.1158/0008-5472.CAN-22-3471.
    PubMed     Abstract available
    
    
    
34. YU S, Wang Y, Gong X, Fan Z, et al
    LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity.
    Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015.
    PubMed     Abstract available
    
    
    
35. HERMIDA-PRADO F, Xie Y, Sherman S, Nagy Z, et al
    Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer.
    Cancer Res. 2023 Jul 14:CAN-23-1711. doi: 10.1158/0008-5472.CAN-23-1711.
    PubMed     Abstract available
    
    
    
36. ACETO N, Gvozdenovic A
    Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
    Cancer Res. 2023 Jul 7:CAN-23-1978. doi: 10.1158/0008-5472.CAN-23-1978.
    PubMed     Abstract available
    
    
    
37. MARIN A, Mamun AA, Patel H, Akamatsu H, et al
    Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer.
    Cancer Res. 2023 Jul 5:CAN-22-3617. doi: 10.1158/0008-5472.CAN-22-3617.
    PubMed     Abstract available
    
    
    
38. NULL JL, Kim DJ, McCann JV, Pramoonjago P, et al
    Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.
    Cancer Res. 2023;83:2105-2122.
    PubMed     Abstract available
    
    
    
39. KA NL, Park MK, Kim SS, Jeon Y, et al
    NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling.
    Cancer Res. 2023 Jul 3:CAN-23-0329. doi: 10.1158/0008-5472.CAN-23-0329.
    PubMed     Abstract available
    
    
    June 2023
40. FATTORI S, Le Roy A, Houacine J, Robert L, et al
    CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
    Cancer Res. 2023 Jun 28:CAN-23-0613. doi: 10.1158/0008-5472.CAN-23-0613.
    PubMed     Abstract available
    
    
    
41. LI B, Qi F, Zhu F, Lu Z, et al
    Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.
    Cancer Res. 2023 Jun 16:CAN-22-3559. doi: 10.1158/0008-5472.CAN-22-3559.
    PubMed     Abstract available
    
    
    
42. JAILKHANI N, Clauser KR, Mak HH, Rickelt S, et al
    Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
    Cancer Res. 2023;83:2052-2065.
    PubMed     Abstract available
    
    
    
43. LI Z, Li T, Yates ME, Wu Y, et al
    The EstroGene database reveals diverse temporal, context-dependent, and bidirectional estrogen receptor regulomes in breast cancer.
    Cancer Res. 2023 Jun 5:CAN-23-0539. doi: 10.1158/0008-5472.CAN-23-0539.
    PubMed     Abstract available
    
    
    
44. CHENG X, Sun Y, Highkin M, Vemalapally N, et al
    Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance.
    Cancer Res. 2023 Jun 5:CAN-22-3558. doi: 10.1158/0008-5472.CAN-22-3558.
    PubMed     Abstract available
    
    
    May 2023
45. RODA N, Cossa A, Hillje R, Tirelli A, et al
    A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer.
    Cancer Res. 2023 May 3:CAN-22-2717. doi: 10.1158/0008-5472.CAN-22-2717.
    PubMed     Abstract available
    
    
    
46. PENG WT, Jin X, Xu XE, Yang YS, et al
    Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2023 May 2:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-2143.
    PubMed     Abstract available
    
    
    April 2023
47. GOU X, Kim BJ, Anurag M, Lei JT, et al
    Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer.
    Cancer Res. 2023 Apr 18:CAN-22-3484. doi: 10.1158/0008-5472.CAN-22-3484.
    PubMed     Abstract available
    
    
    
48. LU XX, Yang WX, Pei YC, Luo H, et al
    An in vivo CRISPR screen identifies that SNRPC promotes triple-negative breast cancer progression.
    Cancer Res. 2023 Apr 14:CAN-22-0536. doi: 10.1158/0008-5472.CAN-22-0536.
    PubMed     Abstract available
    
    
    
49. KHATPE AS, Dirks R, Bhat-Nakshatri P, Mang H, et al
    TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.
    Cancer Res. 2023;83:1345-1360.
    PubMed     Abstract available
    
    
    
50. SUN Z, Jiang Q, Gao B, Zhang X, et al
    AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis.
    Cancer Res. 2023;83:1264-1279.
    PubMed     Abstract available
    
    
    March 2023
51. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Correction: Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Cancer Res. 2023;83:974.
    PubMed    
    
    
    February 2023
52. MALIK N, Kim YI, Yan H, Tseng YC, et al
    Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer.
    Cancer Res. 2023 Feb 14:CAN-22-2525. doi: 10.1158/0008-5472.CAN-22-2525.
    PubMed     Abstract available
    
    
    January 2023
53. ANSTINE LJ, Majmudar PR, Aponte A, Singh S, et al
    TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis.
    Cancer Res. 2023 Jan 25:CAN-22-3133. doi: 10.1158/0008-5472.CAN-22-3133.
    PubMed     Abstract available
    
    
    
54. DAS C, Adhikari S, Bhattacharya A, Chakraborty S, et al
    Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.
    Cancer Res. 2023 Jan 18:CAN-22-3015. doi: 10.1158/0008-5472.CAN-22-3015.
    PubMed     Abstract available
    
    
    December 2022
55. WEIGEL C, Maczis MA, Palladino END, Green CD, et al
    Sphingosine kinase 2 in stromal fibroblasts creates a hospitable tumor microenvironment in breast cancer.
    Cancer Res. 2022 Dec 21:CAN-22-1638. doi: 10.1158/0008-5472.CAN-22-1638.
    PubMed     Abstract available
    
    
    
56. LIAO L, Zhang YL, Deng L, Chen C, et al
    Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer.
    Cancer Res. 2022 Dec 9:CAN-22-2709. doi: 10.1158/0008-5472.CAN-22-2709.
    PubMed     Abstract available
    
    
    
57. WEI L, Gao H, Yu J, Zhang H, et al
    Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer.
    Cancer Res. 2022 Dec 5:CAN-22-1016. doi: 10.1158/0008-5472.CAN-22-1016.
    PubMed     Abstract available
    
    
    November 2022
58. STEVENS LE, Peluffo G, Qiu X, Temko D, et al
    JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states.
    Cancer Res. 2022 Nov 21:CAN-22-0423. doi: 10.1158/0008-5472.CAN-22-0423.
    PubMed     Abstract available
    
    
    
59. WANG F, Moon W, Letsou W, Sapkota Y, et al
    Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    Cancer Res. 2022 Nov 10. pii: 710536. doi: 10.1158/0008-5472.CAN-22-1888.
    PubMed     Abstract available
    
    
    
60. GONG P, Chin SL, Allen WM, Ballal H, et al
    Quantitative Micro-Elastography Enables In Vivo Detection of Residual Cancer in the Surgical Cavity during Breast-Conserving Surgery.
    Cancer Res. 2022;82:4093-4104.
    PubMed     Abstract available
    
    
    
61. PERRONE M, Chiodoni C, Lecchi M, Botti L, et al
    ATF3 reprograms the bone marrow niche in response to early breast cancer transformation.
    Cancer Res. 2022 Nov 1. pii: 710151. doi: 10.1158/0008-5472.CAN-22-0651.
    PubMed     Abstract available
    
    
    October 2022
62. HALPERIN C, Hey J, Weichenhan D, Stein Y, et al
    Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma.
    Cancer Res. 2022 Oct 26:OF1-OF14. doi: 10.1158/0008-5472.CAN-22-0209.
    PubMed     Abstract available
    
    
    
63. BASSIOUNI R, Idowu MO, Gibbs LD, Robila V, et al
    Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer.
    Cancer Res. 2022 Oct 25. pii: 710045. doi: 10.1158/0008-5472.CAN-22-2682.
    PubMed     Abstract available
    
    
    
64. HARGROVE-WILEY E, Fingleton B
    Sex hormones in breast cancer immunity.
    Cancer Res. 2022 Oct 24. pii: 709945. doi: 10.1158/0008-5472.CAN-22-1829.
    PubMed     Abstract available
    
    
    
65. TARANTINO P, Tolaney SM
    The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
    Cancer Res. 2022;82:3659-3661.
    PubMed     Abstract available
    
    
    
66. BLAWSKI R, Toska E
    A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
    Cancer Res. 2022;82:3668-3670.
    PubMed     Abstract available
    
    
    
67. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    PubMed     Abstract available
    
    
    
68. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    PubMed     Abstract available
    
    
    
69. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    PubMed     Abstract available
    
    
    September 2022
70. TOKURA M, Nakayama J, Prieto-Vila M, Shiino S, et al
    Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
    Cancer Res. 2022;82:3236-3248.
    PubMed     Abstract available
    
    
    
71. LIU H, Lyu H, Jiang G, Chen D, et al
    ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer.
    Cancer Res. 2022 Sep 7. pii: 709106. doi: 10.1158/0008-5472.CAN-22-0800.
    PubMed     Abstract available
    
    
    August 2022
72. FATTORI S, Roux H, Connen E, Robert L, et al
    Therapeutic targeting of tumor-infiltrating regulatory T cells in breast cancer.
    Cancer Res. 2022 Aug 30. pii: 708918. doi: 10.1158/0008-5472.CAN-22-0654.
    PubMed     Abstract available
    
    
    
73. GUO Q, Wang H, Duan J, Luo W, et al
    An alternatively spliced p62 isoform confers resistance to chemotherapy in breast cancer.
    Cancer Res. 2022 Aug 29. pii: 708925. doi: 10.1158/0008-5472.CAN-22-0909.
    PubMed     Abstract available
    
    
    
74. NANDI A, Debnath R, Nayak A, To TKJ, et al
    Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer.
    Cancer Res. 2022 Aug 24. pii: 708708. doi: 10.1158/0008-5472.CAN-21-1225.
    PubMed     Abstract available
    
    
    
75. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.
    Cancer Res. 2022 Aug 18. pii: 708038. doi: 10.1158/0008-5472.CAN-22-0900.
    PubMed     Abstract available
    
    
    
76. MOASSER MM
    Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
    Cancer Res. 2022;82:2811-2820.
    PubMed     Abstract available
    
    
    
77. ALTWEGG KA, Viswanadhapalli S, Mann M, Chakravarty D, et al
    A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer.
    Cancer Res. 2022 Aug 11. pii: 707658. doi: 10.1158/0008-5472.CAN-22-0698.
    PubMed     Abstract available
    
    
    
78. NARDONE A, Qiu X, Spisak S, Nagy Z, et al
    A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Cancer Res. 2022 Aug 11. pii: 707656. doi: 10.1158/0008-5472.CAN-21-3186.
    PubMed     Abstract available
    
    
    
79. WU C, Jarrett AM, Zhou Z, Elshafeey N, et al
    MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.
    Cancer Res. 2022 Aug 1. pii: 707362. doi: 10.1158/0008-5472.CAN-22-1329.
    PubMed     Abstract available
    
    
    July 2022
80. TIMPERI E, Gueguen P, Molgora M, Magagna I, et al
    Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.
    Cancer Res. 2022 Jul 21. pii: 707127. doi: 10.1158/0008-5472.CAN-22-1427.
    PubMed     Abstract available
    
    
    
81. CHEN F, Park SL, Wilkens LR, Wan P, et al
    Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    Cancer Res. 2022 Jul 14. pii: 707009. doi: 10.1158/0008-5472.CAN-21-4461.
    PubMed     Abstract available
    
    
    June 2022
82. KALRA R, Chen CH, Wang J, Salam AB, et al
    Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer.
    Cancer Res. 2022 Jun 23. pii: 705013. doi: 10.1158/0008-5472.CAN-21-3106.
    PubMed     Abstract available
    
    
    
83. CLARIDGE SE, Hopkins BD
    PI3King the Environment for Growth: PI3K Activation Drives Transcriptome Changes That Support Oncogenic Growth.
    Cancer Res. 2022;82:2216-2218.
    PubMed     Abstract available
    
    
    
84. LADEWIG E, Michelini F, Jhaveri K, Castel P, et al
    The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
    Cancer Res. 2022;82:2269-2280.
    PubMed     Abstract available
    
    
    
85. ZHANG Z, Golomb L, Meyerson M
    Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Cancer Res. 2022;82:2171-2184.
    PubMed     Abstract available
    
    
    May 2022
86. KOPANJA D, Chand V, O'Brien EM, Mukhopadhyay NK, et al
    Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.
    Cancer Res. 2022 May 18. pii: 699021. doi: 10.1158/0008-5472.CAN-22-0410.
    PubMed     Abstract available
    
    
    
87. WEI YT, Wang XR, Yan C, Huang F, et al
    Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis.
    Cancer Res. 2022;82:1991-2002.
    PubMed     Abstract available
    
    
    
88. FATHERREE JP, Guarin JR, McGinn RA, Naber SP, et al
    Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase.
    Cancer Res. 2022;82:2031-2044.
    PubMed     Abstract available
    
    
    
89. MARCZYK M, Gunasekharan V, Casadevall D, Qing T, et al
    Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
    Cancer Res. 2022;82:1698-1711.
    PubMed     Abstract available
    
    
    April 2022
90. RODRIGUEZ-TIRADO C, Kale N, Carlini MJ, Shrivastava N, et al
    NR2F1 is a barrier to dissemination of early stage breast cancer cells.
    Cancer Res. 2022 Apr 26. pii: 694636. doi: 10.1158/0008-5472.CAN-21-4145.
    PubMed     Abstract available
    
    
    
91. SINGH S, Lee N, Pedroza DA, Bado IL, et al
    Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.
    Cancer Res. 2022 Apr 20. pii: 694629. doi: 10.1158/0008-5472.CAN-21-3714.
    PubMed     Abstract available
    
    
    
92. QUIROS-GONZALEZ I, Tomaszewski MR, Golinska MA, Brown E, et al
    Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
    Cancer Res. 2022;82:1658-1668.
    PubMed     Abstract available
    
    
    
93. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available
    
    
    
94. WANG H, Xu H, Chen W, Cheng M, et al
    Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk.
    Cancer Res. 2022 Apr 8. pii: 694330. doi: 10.1158/0008-5472.CAN-21-4097.
    PubMed     Abstract available
    
    
    
95. ELWAKEEL E, Bruggemann M, Wagih J, Lityagina O, et al
    Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis.
    Cancer Res. 2022;82:1380-1395.
    PubMed     Abstract available
    
    
    
96. HONG Z, Liu T, Wan L, Fa P, et al
    Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy.
    Cancer Res. 2022;82:1298-1312.
    PubMed     Abstract available
    
    
    March 2022
97. SAMANTA D, Park Y, Andrabi SA, Shelton LM, et al
    Correction: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
    Cancer Res. 2022;82:1153.
    PubMed    
    
    
    
98. WILSON Z, Odedra R, Wallez Y, Wijnhoven PWG, et al
    ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer Res. 2022;82:1140-1152.
    PubMed     Abstract available
    
    
    
99. GILKES DM, Chaturvedi P, Bajpai S, Wong CC, et al
    Editor's Note: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis.
    Cancer Res. 2022;82:943.
    PubMed    
    
    
    February 2022
100. BHATIA S, Kramer M, Russo S, Naik P, et al
     Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics.
     Cancer Res. 2022 Feb 18. pii: 681619. doi: 10.1158/0008-5472.CAN-21-2807.
     PubMed     Abstract available
     
     
     
101. CHU W, Zhang X, Qi L, Fu Y, et al
     Correction: The EZH2-PHACTR2-AS1- Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
     Cancer Res. 2022;82:735.
     PubMed    
     
     
     
102. SCHEIDMANN MC, Castro-Giner F, Strittmatter K, Krol I, et al
     An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
     Cancer Res. 2022;82:681-694.
     PubMed     Abstract available
     
     
     
103. LIAO C, Glodowski CR, Fan C, Liu J, et al
     Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
     Cancer Res. 2022;82:665-680.
     PubMed     Abstract available
     
     
     
104. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
     Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
     Cancer Res. 2022;82:615-631.
     PubMed     Abstract available
     
     
     
105. LI XQ, Zhang R, Lu H, Yue XM, et al
     Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells.
     Cancer Res. 2022 Feb 11. pii: 0008-5472.CAN-21-1331.
     PubMed     Abstract available
     
     
     January 2022
106. LI Z, Wu Y, Yates ME, Tasdemir N, et al
     Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.
     Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-2576.
     PubMed     Abstract available
     
     
     
107. MAJORINI MT, Colombo MP, Lecis D
     Few, but efficient: the role of mast cells in breast cancer and other solid tumors.
     Cancer Res. 2022 Jan 19. pii: 0008-5472.CAN-21-3424.
     PubMed     Abstract available
     
     
     
108. HAJ-SHOMALY J, Vorontsova A, Barenholz-Cohen T, Levi-Galibov O, et al
     T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
     Cancer Res. 2022;82:278-291.
     PubMed     Abstract available
     
     
     
109. ZHU WJ, Chen X, Guo XY, Liu HT, et al
     Low glucose-induced overexpression of HOXC-AS3 promotes metabolic reprogramming of breast cancer.
     Cancer Res. 2022 Jan 14. pii: 0008-5472.CAN-21-1179.
     PubMed     Abstract available
     
     
     December 2021
110. XU Y, Ren W, Li Q, Duan C, et al
     LncRNA Uc003xsl.1-mediated activation of the NF-kappaB/IL8 axis promotes progression of triple-negative breast cancer.
     Cancer Res. 2021 Dec 29. pii: 0008-5472.CAN-21-1446.
     PubMed     Abstract available
     
     
     
111. BEETHAM H, Griffith BGC, Murina O, Loftus AE, et al
     Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors.
     Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-0373.
     PubMed     Abstract available
     
     
     
112. OBA T, Kajihara R, Yokoi T, Repasky EA, et al
     Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors.
     Cancer Res. 2021;81:6183-6195.
     PubMed     Abstract available
     
     
     
113. MOORE J, Ma L, Lazar A, Barcellos-Hoff MH, et al
     Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.
     Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0253.
     PubMed     Abstract available
     
     
     November 2021
114. CHOI SR, Hwang CY, Lee J, Cho KH, et al
     Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
     Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
     PubMed     Abstract available
     
     
     
115. YUAN H, Yan L, Wu M, Shang Y, et al
     Analysis of the estrogen receptor-associated lncRNA landscape identifies a role for ERLC1 in breast cancer progression.
     Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-1155.
     PubMed     Abstract available
     
     
     
116. SUBRAMANIAN S, Daquinag AC, AghaAmiri S, Ghosh SC, et al
     Characterization of Peptides Targeting Metastatic Tumor Cells as Probes for Cancer Detection and Vehicles for Therapy Delivery.
     Cancer Res. 2021;81:5756-5764.
     PubMed     Abstract available
     
     
     
117. JANJANAM J, Pano G, Wang R, Minden-Birkenmaier BA, et al
     Matricellular Protein WISP2 Is an Endogenous Inhibitor of Collagen Linearization and Cancer Metastasis.
     Cancer Res. 2021;81:5666-5677.
     PubMed     Abstract available
     
     
     
118. XING F, Liu Y, Wu SY, Wu K, et al
     Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
     Cancer Res. 2021;81:5582.
     PubMed    
     
     
     
119. DAMODARAN S, Hortobagyi GN
     Estrogen Receptor: A Paradigm for Targeted Therapy.
     Cancer Res. 2021;81:5396-5398.
     PubMed     Abstract available
     
     
     
120. GRISARU-TAL S, Dulberg S, Beck L, Zhang C, et al
     Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
     Cancer Res. 2021;81:5555-5571.
     PubMed     Abstract available
     
     
     
121. TEMPS C, Lietha D, Webb ER, Li XF, et al
     A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
     Cancer Res. 2021;81:5438-5450.
     PubMed     Abstract available
     
     
     
122. HINSHAW DC, Hanna A, Lama-Sherpa T, Metge B, et al
     Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages.
     Cancer Res. 2021;81:5425-5437.
     PubMed     Abstract available
     
     
     October 2021
123. PATEL A, Garcia-Closas M, Olshan AF, Perou CM, et al
     Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients.
     Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1207.
     PubMed     Abstract available
     
     
     
124. DONE SJ, Kanwar N, Balde Z, Nair R, et al
     Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response.
     Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1079.
     PubMed     Abstract available
     
     
     
125. GOU X, Anurag M, Lei JT, Kim BJ, et al
     Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer.
     Cancer Res. 2021 Oct 28. pii: 0008-5472.CAN-21-1256.
     PubMed     Abstract available
     
     
     
126. HUGGINS DN, LaRue RS, Wang Y, Knutson TP, et al
     Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
     Cancer Res. 2021;81:5284-5295.
     PubMed     Abstract available
     
     
     
127. WOITEK R, McLean MA, Ursprung S, Rueda OM, et al
     Hyperpolarized carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients.
     Cancer Res. 2021 Oct 8. pii: 0008-5472.CAN-21-1499.
     PubMed     Abstract available
     
     
     September 2021
128. LIU C, Qiang J, Deng Q, Xia J, et al
     ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
     Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
     PubMed     Abstract available
     
     
     
129. ZHAO X, Li J, Liu Z, Powers S, et al
     Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
     Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
     PubMed     Abstract available
     
     
     
130. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
     Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
     Cancer Res. 2021;81:4723-4735.
     PubMed     Abstract available
     
     
     
131. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
     Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
     Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
     PubMed     Abstract available
     
     
     August 2021
132. PULEO J, Polyak K
     The MCF10 Model of Breast Tumor Progression.
     Cancer Res. 2021;81:4183-4185.
     PubMed     Abstract available
     
     
     
133. APOSTOLIDI M, Vathiotis IA, Muthusamy V, Gaule P, et al
     Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
     Cancer Res. 2021;81:4346-4359.
     PubMed     Abstract available
     
     
     July 2021
134. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
     Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
     Cancer Res. 2021;81:3495-3508.
     PubMed     Abstract available
     
     
     
135. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
     Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
     Cancer Res. 2021;81:3449-3460.
     PubMed     Abstract available
     
     
     
136. CHOI H, Kwon J, Cho MS, Sun Y, et al
     Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
     Cancer Res. 2021;81:3607-3620.
     PubMed     Abstract available
     
     
     
137. YOO KH, Tang JJ, Rashid MA, Cho CH, et al
     Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.
     Cancer Res. 2021;81:3727-3737.
     PubMed     Abstract available
     
     
     June 2021
138. BHAN A, Ansari KI, Chen MY, Jandial R, et al
     Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
     Cancer Res. 2021;81:3200-3214.
     PubMed     Abstract available
     
     
     
139. ZHOU Q, Howard ME, Tu X, Zhu Q, et al
     Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
     Cancer Res. 2021;81:3333-3346.
     PubMed     Abstract available
     
     
     May 2021
140. YANG B, Li X, Fu Y, Guo E, et al
     MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
     Cancer Res. 2021;81:2714-2729.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.